HC Wainwright reissued their buy rating on shares of TG Therapeutics Inc. (NASDAQ:TGTX) in a research note issued to investors on Saturday. HC Wainwright currently has a $18.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $22.00.

A number of other equities research analysts also recently weighed in on TGTX. Zacks Investment Research downgraded shares of TG Therapeutics from a strong-buy rating to a hold rating in a research note on Thursday, July 14th. Roth Capital reiterated a buy rating and set a $33.00 price target on shares of TG Therapeutics in a research note on Wednesday, August 10th. S&P Equity Research decreased their price target on shares of TG Therapeutics from $7.15 to $6.40 in a research note on Wednesday, August 24th. FBR & Co reiterated a buy rating on shares of TG Therapeutics in a research note on Monday, September 19th. Finally, Brean Capital reiterated a buy rating and set a $28.00 price target on shares of TG Therapeutics in a research note on Thursday, October 6th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. TG Therapeutics has a consensus rating of Buy and a consensus target price of $21.21.

TG Therapeutics (NASDAQ:TGTX) traded down 3.80% during trading on Friday, reaching $6.59. 1,109,795 shares of the company’s stock traded hands. The company’s market capitalization is $358.87 million. The firm’s 50 day moving average is $7.39 and its 200-day moving average is $7.37. TG Therapeutics has a 12 month low of $5.41 and a 12 month high of $14.87.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative return on equity of 58.77% and a negative net margin of 40,142.11%. Analysts expect that TG Therapeutics will post ($1.22) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Advisors LLC increased its position in shares of TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,296 shares during the period. Mariner Wealth Advisors LLC increased its position in shares of TG Therapeutics by 4.4% in the second quarter. Mariner Wealth Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 800 shares during the period. SECOR Capital Advisors LP bought a new position in shares of TG Therapeutics during the second quarter valued at about $187,000. Emerald Acquisition Ltd. bought a new position in shares of TG Therapeutics during the second quarter valued at about $190,000. Finally, Rhumbline Advisers increased its position in shares of TG Therapeutics by 9.0% in the second quarter. Rhumbline Advisers now owns 37,547 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 3,107 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

5 Day Chart for NASDAQ:TGTX

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.